申请人:Sumitomo Dainippon Pharma Co., Ltd.
公开号:EP3006438A1
公开(公告)日:2016-04-13
The present invention provides a cyclic aminomethyl pyrimidine derivative and a pharmaceutically acceptable salt thereof with high selectivity for dopamine D4 receptors, which are useful for treating a disease such as attention deficit hyperactivity disorder. Specifically, a compound of formula (1) or a pharmaceutically acceptable salt thereof is provided, wherein n and m are independently 1 or 2; Ra is C1-6 alkyl group, C3-6 cycloalkyl group, or amino group; Rb is hydrogen atom, C1-6 alkyl group or the like, provided that when Ra is amino group, then Rb is hydrogen atom; Rc1 and Rc2 are independently hydrogen atom, or C1-6 alkyl group; Rd1 and Rd2 are independently hydrogen atom, fluorine atom or the like; ring Q is an optionally-substituted pyridyl group or an optionally-substituted isoquinolyl group; and the bond having a dashed line is a single or double bond.
本发明提供了一种对多巴胺D4受体具有高选择性的环氨甲基嘧啶衍生物及其药学上可接受的盐,可用于治疗注意力缺陷多动障碍等疾病。具体而言,提供了式(1)化合物或其药学上可接受的盐,其中n和m独立地为1或2;Ra为C1-6烷基、C3-6环烷基或氨基;Rb为氢原子、C1-6烷基或类似物,但当Ra为氨基时,则Rb为氢原子;Rc1 和 Rc2 独立地为氢原子或 C1-6 烷基;Rd1 和 Rd2 独立地为氢原子、氟原子或类似物;环 Q 为任选取代的吡啶基或任选取代的异喹啉基;带虚线的键为单键或双键。